Amryt Pharma Share Discussion Threads

[timbo003] 05/12/2016 23:23

>>>8881CB

I think they were referring to the Stifel target in the article


In which case it should have been 49p, not 59p (see link below for full report)....but I suspect most shareholders would settle for 49p in the short term:

[888icb] 05/12/2016 21:56

In the proactive article a target by one broker is referred to and it's 59p.

[timbo003] 05/12/2016 18:21

Here's the link to the video referred to in the post above:

[cpap man] 05/12/2016 17:38

Dear Proactive Investor

For the second working day in a row, Amryt’s boss Joe Wiley has been in the Proactive Investors office with some terrific news.

Today’s news, about a licensing deal for a drug that treats a horrible cholesterol condition, was even more of a blockbuster than last Friday’s funding deal, and sent the share price soaring to 20p from 16.5p overnight, though some of the profits had been creamed off by the close.

In our lead item, Ian Lyall explains the significance of the deal, which will not cost the company any money but which will provide it with a means of generating cash.

In our Stocktube section, Wiley himself tells our presenter Charlotte Kan a little bit more about the disease the drug treats and what the licensing deal entails.

ETC....

[alphabravo321] 05/12/2016 15:59

Little run into the close?

[buffythebuffoon] 05/12/2016 14:37

Indeed, who can?

I hope he's alright...too much excitement and all that.

Buffy

[pottermagic2310] 05/12/2016 12:55

Good to see there are multiple products (in-house and 3rd Party) that offer Revenue pipelines. Lots more like this over the next 6 months could see this take off and with the recent low of 13.5p having provided a good opportunity, who can complain right now
;-)

[papillon] 05/12/2016 12:46

The odds are good here; much better than with most speculative AIM stocks. Why? We have a good, experienced, BoD (they've been there before and got the tee shirt!) and orphan drugs appears to be a good business to be in. We could make money and be satisfied that the company is doing something laudable and worthwhile. We can sleep easy something that might not be possible if invested in an O&G company (global warming concerns).

AMYT could prove to be a multi-bagger over the next few years for the patient investor. Only time will tell. No one can predict the future, but the odds look good to me.

[papillon] 05/12/2016 12:35

papillon - 30 Nov 2016 - 18:28:49 - 595 of 661 Amryt Pharma - AMYT
Could be a good time to add? Who can know? I have no idea! I can't predict the future (unfortunately!).

Me? I going to put my AMYT shares in the bottom drawer (metaphorically since they are held in a nominee a/c) and wait for the news to flow (and it will, be it within the next month, or next year). Not even worth speculating until we get news.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Well the good news did "flow" and it arrived EARLY.

[buffythebuffoon] 05/12/2016 10:44

There's nothing like having someone who has done it before. There are many nuances I'm sure that we wouldn't even know about that Harry can help with, not to mention his contacts, as you imply.

I knew Mark years ago, and he made a very courageous move from a previous career.

He's earning his money already..

Buffy

[alphabravo321] 05/12/2016 10:41

Hopefully the same logic applies to H Stratford when it comes to him getting one his pals from Big Pharma to buy the company...

[buffythebuffoon] 05/12/2016 10:30

Now you see why Mark Sumeray was appointed.

Buffy

[alphabravo321] 05/12/2016 10:30

Nice little day so far, slow and steady wins the race!

[icebreaker] 05/12/2016 09:03

Rossannan

Good point. I suspect this may be the first of other deals with this company. Novelion (parent company) seem to have other products which suit our model (subject to approval in our territories)..

[alphabravo321] 05/12/2016 08:15

A little MM pullback

[talkman2] 05/12/2016 08:11

Surprised this hasn't cleared 20p yet on today's news coupled with Fridays .

[bigwavedave] 05/12/2016 08:07

Another cracking piece of news.

[cpap man] 05/12/2016 08:03

Amryt Pharma (AMYT.L, 16.50p) – Speculative Buy

Amryt Pharma plc, the clinical stage specialty pharmaceutical company focused on best in class treatments for orphan diseases, on Friday, announced that it has entered into a €20m Facility Agreement with the European Investment Bank ('EIB'), a leading European investment body. The Facility has an interest rate of 3% over the Euro Interbank Offered Rate to be paid periodically, with a further 10% accruing and payable in a bullet together with the outstanding principal amount on expiry of the Facility. The Facility has a 5-year term from drawdown and the associated repayment schedule is expected to present a minimal cash burden to the Group during the term, ahead of repayment. The Facility is split into three tranches; €10m available immediately and two further tranches of €5m available upon the achievement of certain milestones in relation to the Group's lead product, Episalvan. The Group has already submitted its protocol for the pivotal Phase III study for Episalvan, to test its safety and efficacy profile for the treatment of Epidermolysis Bullosa ('EB'), which has been granted US and EU orphan drug designation. The Phase III clinical trial in EB is expected to be commence in Q1 FY2017 with top-line data anticipated to be available in mid-2018 and commercial launch expected in 2019. European Investment Bank's Vice President, Andrew McDowell commented "Continued investment in innovation is crucial to improve lives and build on European strengths to develop world-leading pharmaceutical products. The European Investment Bank is pleased to support innovation and development of new treatment of painful skin disorders by Amryt Pharma. This represents the EIB's first-ever direct support for investment by an Irish pharma company and I am pleased to confirm the EIB's intention to increase support for private sector innovation in Ireland in the years ahead".

Our view: This is a significant milestone for Amryt. The Facility fully funds the pivotal Phase III study for Episalvan at an attractive rate without the need for dilution to shareholders. Episalvan received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016 and Amryt is developing Episalvan as a new treatment for EB, a rare and inherited skin disorder that causes the skin to become very fragile, affecting c.500,000 patients worldwide, for which, there is currently no available treatment. The EB market in the US and Europe alone is estimated to be worth c.US$1.5bn per annum. The Group has patent for the use of Episalvan in the treatment of EB in US and Europe for the treatment of all partial thickness wounds, including those derived from EB. The Facility also provides the funding required to progress its earlier stage AP102, a US orphan designated acromegaly drug compound through pre-clinical development and into the clinic. AP102 focuses on somatostatin analogue peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. Shareholders cheered on Friday as Amryt showed its ability to secure Facility Agreement with EIB, a high profile long-term lending institution owned by the Member States of the European Union, demonstrating their confidence in management's capability to progress it pipelines of products, particularly the Episalvan. The Group has acted in shareholder's best interests and we look forward to further updates in due course. Beaufort reiterate a Speculative Buy rating on the Shares.

[icebreaker] 05/12/2016 07:47

Potentially $3M in sales straight away!

[cpap man] 05/12/2016 07:40

Joe Wiley, CEO of Amryt, commented:



"We are delighted to announce this landmark licensing deal. It transforms Amryt into a fully-fledged commercial orphan pharma company and comes only eight months after Amryt's IPO in April.



This agreement with Aegerion Pharmaceuticals gives us an exclusive licence to sell LOJUXTA across the EEA, MENA and other territories for the treatment of a very rare and life-threatening disease - Homozygous Familial Hypercholesterolaemia - or HoFH - where there is significant unmet need.



If left untreated, HoFH may cause heart attacks, strokes or sudden death in childhood or early adulthood. We believe that LOJUXTA, which was approved in the EEA in late 2013, has the potential to become a mainstay treatment in the management of HoFH. Given our in-depth knowledge of the drug we are confident that we can enhance sales of this product going forward.



The Company has made significant strides since flotation. This agreement enables Amryt to generate material cash flows from the commercial sales of a drug which is well known to us. We will also be in a position to leverage the pan-European LOJUXTA commercial, medical and regulatory infrastructure when we launch our lead asset, Episalvan, upon successful completion of the Phase 3 clinical trial in Epidermolysis Bullosa, expected in 2018.



This agreement is tremendously exciting and underlines our clear focus on building our portfolio of medicines to treat rare and orphan diseases, where there is large unmet medical need. We look forward providing a further update in due course."

[cpap man] 05/12/2016 07:28

5 December 2016
AIM: AMYT

ESM: AYP

Amryt Pharma plc

("Amryt" or the "Company")



Secures Exclusive Licence

For Drug to Treat Rare Disease,

Homozygous Familial Hypercholesterolaemia ("HoFH")



Amryt, a clinical-stage specialty pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce that it has reached an agreement with Aegerion Pharmaceuticals, Inc. ("Aegerion"), the NASDAQ-listed biopharmaceutical company, for the exclusive rights to sell Aegerion's drug, LOJUXTA (lomitapide), across the European Union ("EU") and other territories (the "Licence Agreement"). The Licence Agreement will add to the Company's growing portfolio of orphan products and is expected to be immediately cash generative for Amryt.

Etc....

[alphabravo321] 04/12/2016 10:21

I wonder where we would be had we come into the IPO with this finance facility in place?! Would we have seen the lows?